Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM pat...

Full description

Bibliographic Details
Main Authors:	Yoshizawa, S, Ohyashiki, J H, Ohyashiki, M, Umezu, T, Suzuki, K, Inagaki, A, Iida, S, Ohyashiki, K
Format:	Online
Language:	English
Published:	Nature Publishing Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270255/

id	pubmed-3270255
recordtype	oai_dc
spelling	pubmed-32702552012-02-02 Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders Yoshizawa, S Ohyashiki, J H Ohyashiki, M Umezu, T Suzuki, K Inagaki, A Iida, S Ohyashiki, K Original Article Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects (P<0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8+ or CD4+ cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients. Nature Publishing Group 2012-01 2012-01-20 /pmc/articles/PMC3270255/ /pubmed/22829237 http://dx.doi.org/10.1038/bcj.2011.51 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Yoshizawa, S Ohyashiki, J H Ohyashiki, M Umezu, T Suzuki, K Inagaki, A Iida, S Ohyashiki, K
spellingShingle	Yoshizawa, S Ohyashiki, J H Ohyashiki, M Umezu, T Suzuki, K Inagaki, A Iida, S Ohyashiki, K Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
author_facet	Yoshizawa, S Ohyashiki, J H Ohyashiki, M Umezu, T Suzuki, K Inagaki, A Iida, S Ohyashiki, K
author_sort	Yoshizawa, S
title	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
title_short	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
title_full	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
title_fullStr	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
title_full_unstemmed	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
title_sort	downregulated plasma mir-92a levels have clinical impact on multiple myeloma and related disorders
description	Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects (P<0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8+ or CD4+ cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients.
publisher	Nature Publishing Group
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270255/
_version_	1611503171783360512

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

Similar Items